Manzella L - Search Results

1

IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.

Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, Morrone G, Sciacca L, Di Raimondo F, Manzella L, Vigneri P. Massimino M, et al. Among authors: manzella l. Carcinogenesis. 2014 May;35(5):1132-43. doi: 10.1093/carcin/bgu013. Epub 2014 Jan 20. Carcinogenesis. 2014. PMID: 24445143

2

Role of interferon regulatory factor 1 in monocyte/macrophage differentiation.

Manzella L, Conte E, Cocchiaro G, Guarniera E, Sciacca B, Bonaiuto C, Stagno F, Messina A. Manzella L, et al. Eur J Immunol. 1999 Sep;29(9):3009-16. doi: 10.1002/(SICI)1521-4141(199909)29:09<3009::AID-IMMU3009>3.0.CO;2-H. Eur J Immunol. 1999. PMID: 10508275 Free article.

3

Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.

Tirrò E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A, Vigneri P. Tirrò E, et al. Among authors: manzella l. Cancer Res. 2006 Apr 15;66(8):4263-72. doi: 10.1158/0008-5472.CAN-05-3248. Cancer Res. 2006. PMID: 16618750

4

Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded.

Buffa P, Manzella L, Consoli ML, Messina A, Vigneri P. Buffa P, et al. Among authors: manzella l. Proteins. 2007 Apr 1;67(1):1-11. doi: 10.1002/prot.21161. Proteins. 2007. PMID: 17211892

5

Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia.

Stagno F, Vigneri P, Consoli ML, Cupri A, Stella S, Tambè L, Massimino M, Manzella L, Di Raimondo F. Stagno F, et al. Among authors: manzella l. Acta Haematol. 2012;127(1):7-9. doi: 10.1159/000330607. Epub 2011 Oct 5. Acta Haematol. 2012. PMID: 21986290 No abstract available.

6

IRF5 promotes the proliferation of human thyroid cancer cells.

Massimino M, Vigneri P, Fallica M, Fidilio A, Aloisi A, Frasca F, Manzella L. Massimino M, et al. Among authors: manzella l. Mol Cancer. 2012 Apr 16;11:21. doi: 10.1186/1476-4598-11-21. Mol Cancer. 2012. PMID: 22507190 Free PMC article.

7

Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.

Stella S, Tirrò E, Conte E, Stagno F, Di Raimondo F, Manzella L, Vigneri P. Stella S, et al. Among authors: manzella l. Mol Cancer Ther. 2013 Jun;12(6):1085-98. doi: 10.1158/1535-7163.MCT-12-0550. Epub 2013 Mar 27. Mol Cancer Ther. 2013. PMID: 23536723

8

BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.

Buffa P, Romano C, Pandini A, Massimino M, Tirrò E, Di Raimondo F, Manzella L, Fraternali F, Vigneri PG. Buffa P, et al. Among authors: manzella l. FASEB J. 2014 Mar;28(3):1221-36. doi: 10.1096/fj.13-236992. Epub 2013 Dec 2. FASEB J. 2014. PMID: 24297701

9

The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy.

Vigneri PG, Tirrò E, Pennisi MS, Massimino M, Stella S, Romano C, Manzella L. Vigneri PG, et al. Among authors: manzella l. Front Oncol. 2015 Oct 15;5:230. doi: 10.3389/fonc.2015.00230. eCollection 2015. Front Oncol. 2015. PMID: 26528439 Free PMC article. Review.

10

Biomarkers and prognostic factors for malignant pleural mesothelioma.

Vigneri P, Martorana F, Manzella L, Stella S. Vigneri P, et al. Among authors: manzella l. Future Oncol. 2015;11(24 Suppl):29-33. doi: 10.2217/fon.15.317. Future Oncol. 2015. PMID: 26638920 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74 results

Search Page

Filters